The Oncogenic STP Axis Promotes Triple-Negative Breast Cancer via Degradation of the REST Tumor Suppressor

Cell Reports

Volumn 9, Issue 4, 2014, Pages 1318-1332

  Karlin, Kristen L ^a   Mondal, Gourish ^c   Hartman, Jessica K ^a   Tyagi, Siddhartha ^a   Kurley, Sarah J ^a   Bland, Chris S ^a   Hsu, Tiffany Y T ^a   Renwick, Alexander ^a   Fang, Justin E ^a   Migliaccio, Ilenia ^a   Callaway, Celetta ^a   Nair, Amritha ^a   Dominguez Vidana, Rocio ^a   Nguyen, Don X ^b   Osborne, C Kent ^a   Schiff, Rachel ^a   Yu Lee, Li Yuan ^a   Jung, Sung Y ^a   Edwards, Dean P ^a   Hilsenbeck, Susan G ^a   Rosen, Jeffrey M ^a   Zhang, Xiang H F ^a   Shaw, Chad A ^a   Couch, Fergus J ^c   Westbrook, Thomas F ^a   more..

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLO LIKE KINASE 1; PROTEIN SCYL1; PROTEIN TEX14; REGULATOR PROTEIN; REST TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE BETA TRCP; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; RE1-SILENCING TRANSCRIPTION FACTOR; REPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CELL TRANSFORMATION; CONTROLLED STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; ANIMAL; CARCINOGENESIS; FEMALE; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE AMPLIFICATION; HUMANS; MICE; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84912118947     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.10.011     Document Type: Article

References (52)

1. Archambault V., Glover D.M. Polo-like kinases: conservation anddivergence in their functions and regulation. Nat. Rev. Mol. Cell Biol. 2009, 10:265-275.
2. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 2012, 9:16-32.
3. Ballas N., Mandel G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr. Opin. Neurobiol. 2005, 15:500-506.
4. Ballas N., Grunseich C., Lu D.D., Speh J.C., Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 2005, 121:645-657.
5. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A., et al. Functional viability profiles of breast cancer. Cancer discovery 2011, 1:260-273.
6. Calderone A., Jover T., Noh K.M., Tanaka H., Yokota H., Lin Y., Grooms S.Y., Regis R., Bennett M.V., Zukin R.S. Ischemic insults derepress the gene silencer REST in neurons destined to die. J.Neurosci. 2003, 23:2112-2121.
7. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
8. Chong J.A., Tapia-Ramírez J., Kim S., Toledo-Aral J.J., Zheng Y., Boutros M.C., Altshuller Y.M., Frohman M.A., Kraner S.D., Mandel G. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell 1995, 80:949-957.
9. Collisson E.A., Cho R.J., Gray J.W. What are we learning from the cancer genome?. Nat. Rev. Clin. Oncol. 2012, 9:621-630.
10. Coulson J.M., Edgson J.L., Woll P.J., Quinn J.P. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res. 2000, 60:1840-1844.
11. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
12. Davidson B., Reich R., Lazarovici P., Ann Flørenes V., Nielsen S., Nesland J.M. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res. Treat. 2004, 83:119-128.
13. Degenhardt Y., Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin. Cancer Res. 2010, 16:384-389.
14. Di Cosimo S., Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nat. Rev. Clin. Oncol. 2010, 7:139-147.
15. Dollé L., El Yazidi-Belkoura I., Adriaenssens E., Nurcombe V., Hondermarck H. Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 2003, 22:5592-5601.
16. Fuchs S.Y., Spiegelman V.S., Kumar K.G. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004, 23:2028-2036.
17. Guardavaccaro D., Frescas D., Dorrello N.V., Peschiaroli A., Multani A.S., Cardozo T., Lasorella A., Iavarone A., Chang S., Hernando E., Pagano M. Control of chromosome stability by the beta-TrCP-REST-Mad2 axis. Nature 2008, 452:365-369.
18. Gurrola-Diaz C., Lacroix J., Dihlmann S., Becker C.M., von Knebel Doeberitz M. Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells. Oncogene 2003, 22:5636-5645.
19. Hondermarck H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev. 2012, 23:357-365.
20. Hurvitz S.A., Finn R.S. What's positive about 'triple-negative' breast cancer?. Future Oncol. 2009, 5:1015-1025.
21. Iwamori T., Iwamori N., Ma L., Edson M.A., Greenbaum M.P., Matzuk M.M. TEX14 interacts with CEP55 to block cell abscission. Mol. Cell. Biol. 2010, 30:2280-2292.
22. Johnson D.S., Mortazavi A., Myers R.M., Wold B. Genome-wide mapping of invivo protein-DNA interactions. Science 2007, 316:1497-1502.
23. Kaneko N., Hwang J.Y., Gertner M., Pontarelli F., Zukin R.S. Casein kinase 1 suppresses activation of REST in insulted hippocampal neurons and halts ischemia-induced neuronal death. J.Neurosci. 2014, 34:6030-6039.
24. Kerppola T.K. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat. Protoc. 2006, 1:1278-1286.
25. Kreisler A., Strissel P.L., Strick R., Neumann S.B., Schumacher U., Becker C.M. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 2010, 29:5828-5838.
26. Lagadec C., Meignan S., Adriaenssens E., Foveau B., Vanhecke E., Romon R., Toillon R.A., Oxombre B., Hondermarck H., Le Bourhis X. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 2009, 28:1960-1970.
27. Lens S.M., Voest E.E., Medema R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. Cancer 2010, 10:825-841.
28. Lu T., Aron L., Zullo J., Pan Y., Kim H., Chen Y., Yang T.H., Kim H.M., Drake D., Liu X.S., et al. REST and stress resistance in ageing and Alzheimer's disease. Nature 2014, 507:448-454.
29. Maire V., Némati F., Richardson M., Vincent-Salomon A., Tesson B., Rigaill G., Gravier E., Marty-Prouvost B., De Koning L., Lang G., et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 2013, 73:813-823.
30. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
31. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massagué J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
32. Mondal G., Ohashi A., Yang L., Rowley M., Couch F.J. Tex14, a Plk1-regulated protein, is required for kinetochore-microtubule attachment and regulation of the spindle assembly checkpoint. Mol. Cell 2012, 45:680-695.
33. Moshe Y., Boulaire J., Pagano M., Hershko A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc. Natl. Acad. Sci. USA 2004, 101:7937-7942.
34. Osborne C.K. Tamoxifen in the treatment of breast cancer. N.Engl. J. Med. 1998, 339:1609-1618.
35. Petronczki M., Lénárt P., Peters J.M. Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. Dev. Cell 2008, 14:646-659.
36. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
37. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2011, 5:5-23.
38. Schmidt W.M., Kraus C., Höger H., Hochmeister S., Oberndorfer F., Branka M., Bingemann S., Lassmann H., Müller M., Macedo-Souza L.I., et al. Mutation in the Scyl1 gene encoding amino-terminal kinase-like protein causes a recessive form of spinocerebellar neurodegeneration. EMBO Rep. 2007, 8:691-697.
39. Schoenherr C.J., Anderson D.J. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science 1995, 267:1360-1363.
40. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009, 14:559-570.
41. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
42. Smid M., Wang Y., Zhang Y., Sieuwerts A.M., Yu J., Klijn J.G., Foekens J.A., Martens J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68:3108-3114.
43. Steegmaier M., Hoffmann M., Baum A., Lénárt P., Petronczki M., Krssák M., Gürtler U., Garin-Chesa P., Lieb S., Quant J., et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth invivo. Curr. Biol. 2007, 17:316-322.
44. Wagoner M.P., Gunsalus K.T., Schoenike B., Richardson A.L., Friedl A., Roopra A. The transcription factor REST is lost in aggressive breast cancer. PLoS Genet. 2010, 6:e1000979.
45. Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N., Hunter T., Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc. Natl. Acad. Sci. USA 2004, 101:4419-4424.
46. Watanabe H., Mizutani T., Haraguchi T., Yamamichi N., Minoguchi S., Yamamichi-Nishina M., Mori N., Kameda T., Sugiyama T., Iba H. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 2006, 25:470-479.
47. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., Zhao J.J., Roberts T.M., Mandel G., Hannon G.J., et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005, 121:837-848.
48. Westbrook T.F., Hu G., Ang X.L., Mulligan P., Pavlova N.N., Liang A., Leng Y., Maehr R., Shi Y., Harper J.W., Elledge S.J. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature 2008, 452:370-374.
49. Winston J.T., Strack P., Beer-Romero P., Chu C.Y., Elledge S.J., Harper J.W. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination invitro. Genes Dev. 1999, 13:270-283.
50. Wu M.H., Rajkovic A., Burns K.H., Yan W., Lin Y.N., Matzuk M.M. Sequence and expression of testis-expressed gene 14 (Tex14): a gene encoding a protein kinase preferentially expressed during spermatogenesis. Gene Expr. Patterns 2003, 3:231-236.
51. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818-829.
52. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.